Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BWV-102
- Development stage
- Preclinical
- Lead developer
- Onconetix
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
BWV-102 is a pre-pandemic H1 influenza vaccine candidate being developed by Blue Water Biotech (formerly Blue Water Vaccines). The vaccine utilizes technology licensed from Oxford University Innovation based on computationally identified 'epitopes of limited variability' (ELVs). These ELVs are highly conserved regions of the influenza virus identified through mathematical modeling of virus evolution. By targeting these conserved regions using a virus-like particle (VLP) platform, BWV-102 aims to provide broad and durable protection against H1 influenza strains with pandemic potential, potentially overcoming the need for frequent seasonal updates.
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on BWV-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BWV-102.